CHARLES RIVER LABORATORIES (CRL)

US1598641074 - Common Stock

193.14  +0.17 (+0.09%)

After market: 193.14 0 (0%)

Buy % Consensus

72

ChartMill assigns a Buy % Consensus number of 72% to CRL. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 229.01. This target is 18.57% above the current price.
CRL was analyzed by 24 analysts. The buy percentage consensus is at 72. So analysts seem to be have mildly positive about CRL.
In the previous month the buy percentage consensus was at a similar level.
CRL was analyzed by 24 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 193.14191.90224.40229.01272.17 - -0.64% 16.19% 18.57% 40.92%
Up and Down Grades
Date Firm Action Rating
2024-10-14 Redburn Atlantic Initiate Sell
2024-10-07 Evercore ISI Group Downgrade Outperform -> In-Line
2024-10-02 B of A Securities Downgrade Buy -> Neutral
2024-10-01 Citigroup Downgrade Neutral -> Sell
2024-09-20 Baird Maintains Neutral -> Neutral
2024-08-12 TD Cowen Maintains Hold -> Hold
2024-08-08 UBS Maintains Buy -> Buy
2024-08-08 Barclays Maintains Equal-Weight -> Equal-Weight
2024-08-08 Evercore ISI Group Maintains Outperform -> Outperform
2024-08-08 JP Morgan Downgrade Overweight -> Neutral
2024-08-08 Baird Downgrade Outperform -> Neutral
2024-08-08 Goldman Sachs Maintains Buy -> Buy
2024-07-10 Baird Maintains Outperform -> Outperform
2024-06-28 Argus Research Downgrade Buy -> Hold
2024-06-28 Barclays Initiate Equal-Weight
2024-06-07 Mizuho Initiate Neutral
2024-06-06 Goldman Sachs Initiate Buy
2024-05-13 TD Cowen Maintains Hold -> Hold
2024-05-10 Baird Maintains Outperform -> Outperform
2024-03-18 Argus Research Maintains Buy -> Buy
2024-02-15 Guggenheim Downgrade Buy -> Neutral
2024-02-15 UBS Maintains Buy -> Buy
2024-02-15 Evercore ISI Group Maintains Outperform -> Outperform
2024-02-15 JP Morgan Maintains Overweight -> Overweight
2024-02-15 Baird Maintains Outperform -> Outperform
2024-02-15 Citigroup Maintains Neutral -> Neutral
2023-12-20 JP Morgan Maintains Overweight -> Overweight
2023-12-11 Citigroup Maintains Neutral -> Neutral
2023-11-10 Morgan Stanley Maintains Equal-Weight -> Equal-Weight
2023-11-09 UBS Maintains Buy -> Buy